Elevated Levels of IL-27 Are Associated with Disease Activity in Patients with Crohn’s Disease

Table 1

Clinical characteristics of the CD patients and control subjects.

	Crohn’s disease ()	Control ()
Age (years)	27 (20.25, 31.50)	30 (23, 41.5)	0.160
Gender
Female	13	12	0.140
Male	47	20
Disease duration (months)	30.45 (3.20, 188.10)
Age at diagnosis
A1 (<16 years)	6	—
A2 (16~40 years)	48	—
A3 (>40 years)	6	—
Disease location
L1 (ileum)	21	—
L2 (colon)	6	—
L3 (ileum-colon)	33	—
L4 (upper gastrointestinal tract)	2	—
Disease behavior
B1 (nonstenotic, nonpenetrating)	34	—
B2 (stenotic)	22	—
B3 (penetrating)	4	—
p (perianal)	25	—
Serum IL-27 level (pg/ml)	110.0 (95.0, 145.0)	85.0 (80.0, 95.0)	<0.001
Serum IL-23 level (pg/ml)	23.7 (16.2, 35.9)	20.6 (14.4, 23.6)	0.162
Medical therapy
Mesalazine only	14
Steroids±mesalazine	14
Azathioprine±mesalazine	8
Infliximab±mesalazine	35

Values are expressed as median (interquartile range (IQR)).